2nd Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad - 500034, Telangana, India T +91 40 39804333 / 2342 0500 / 501 F +91 40 3980 4320



January 20, 2020

То	То
The Corporate Relations Department	The Listing Department
BSE Limited	National Stock Exchange of India Limited
Phiroz Jeejeebhoy Towers, 25th Floor,	Exchange Plaza,
Dalal Street	Bandra Kurla Complex, Bandra (East)
Mumbai – 400001	Mumbai – 400 051
Code: 540222	Code: LAURUSLABS

Dear Sirs,

Sub: Board Meeting Intimation

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Thursday, January 30, 2020, *inter-alia*, to consider and approve the Un-audited Financial Results of the Company for the quarter and nine months ended December 31, 2019.

Further, the Company's trading window for dealing in securities by the Directors and Designated Persons has been closed from Wednesday, January 01, 2020, which was already intimated on December 31, 2019, and shall continue to remain closed till Saturday, February 01, 2020 (both days inclusive).

This is for your information and records.

Thanking you,

Yours sincerely, For Laurus Labs Limited

G. Venkateswar Reddy

G. Venkateswar Reddy Company Secretary

Active Pharmaceutical Ingredients & Intermediates



Finished Dosage Forms

Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518 T +91 891 3061222 F +91 891 3061220 E info@lauruslabs.com W lauruslabs.com

AURUS Generics LAURUS Generics LAURUS Synthesis LAURUS Ingredients

Contract Development & Manufacturing Services

Specialty Ingredients for Nutraceutical & Allied Industry